Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: HCA stock price vs JAZZ: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at JAZZ's multiple
Needs JAZZ P/E.
Implied fair value · at HCA's multiple
Needs Annual EPS is negative, HCA P/E.
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Eight period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
HCA Healthcare, Inc. · implied price per share
Bear
$130.81
Base
$187.37
Bull
$261.03
Jazz Pharmaceuticals plc · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
LABCORP HOLDINGS INC.
HCA vs LH
WEST PHARMACEUTICAL SERVICES INC
HCA vs WST
BAXTER INTERNATIONAL INC
HCA vs BAX
MCKESSON CORP
HCA vs MCK
Cigna Group
HCA vs CI
UNITEDHEALTH GROUP INC
HCA vs UNH
AMGEN INC
HCA vs AMGN
GILEAD SCIENCES, INC.
HCA vs GILD
VERTEX PHARMACEUTICALS INC / MA
HCA vs VRTX
SUPERNUS PHARMACEUTICALS, INC.
HCA vs SUPN
Vanda Pharmaceuticals Inc.
HCA vs VNDA
PERRIGO Co plc
HCA vs PRGO
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe HCA should trade closer to its JAZZ-implied or DCF valuation rather than its current market price, then a bullish relative-value position in HCA is justified because HCA is materially more profitable and less leveraged than JAZZ while trading at lower multiples across P/S and EV/EBITDA.
HCA trades at 1.2x P/S versus JAZZ at 3.9x, and at 5.4x EV/EBITDA versus JAZZ at 65.5x, despite HCA being the stronger business. The implied price of $1,324.43 implies 220.4% upside versus the current $413.36 price, placing HCA well below both its JAZZ-implied range and its DCF range.
Supporting Metrics
